Figure 6: Oridonin degrades BCR-ABL and exerts anticancer effect in imatinib-sensitive and -resistant leukemia cells in vitro and in vivo.
From: Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia
(a) Oridonin decreases wild-type and mutated BCR-ABL in HL60/p210 cells. HL60 subclones stably expressing wild-type (WT) or mutated (T315I, E255K) BCR-ABL were treated with oridonin for 6 hours and lysed for immunoblotting. (b) Oridonin inhibits cell growth in imatinib-sensitive and -resistant leukemia cells. MTT assays were performed after a 24-hour oridonin treatment or a 48-hour imatinib treatment in HL60 subclones. (c) Oridonin induces apoptosis in imatinib-sensitive and -resistant leukemia cells. Cells were treated with oridonin for 24 hours and subjected to Annexin V/PI staining and flow cytometry. (d,e) Oridonin inhibits tumor growth in HL60/p210wt and HL60/p210T315I xenograft-bearing nude mice as shown by tumor volumes (d) and tumor weights (e). (f) Immunohistochemistry staining of BCR-ABL on tumor sections. Bar = 50 μm. *P < 0.05; **P < 0.01.
